Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Research Article

Vol. 9 No. 1 (2006)

Primary Prevention of Fatal Ventricular Arrhythmias With Implantable Cardioverter- Defibrillator Therapy – An Analysis of Implications Based on MADIT II Criteria

  • Zia I Carrim
  • Ashraf A Khan
  • Shazad Aslam
DOI
https://doi.org/10.26443/mjm.v9i1.745
Submitted
November 12, 2020
Published
2020-12-01

Abstract

Aims: The primary aim of this retrospective study was to determine the proportion of patients with myocardial infarction (MI) who fulfil the criteria of the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II and the implications of MADIT II criteria in practice. Methods: We performed a retrospective analysis of three hundred and ninety four admissions to the Coronary Care Unit (CCU) of the Royal Infirmary of Edinburgh. We selected those with myocardial infarction (MI) and attempted to retrieve electronic copies of their echocardiogram reports. When available, these were used to assess requirement for primary-prevention Implantable Cardioverter Defibrillator (ICD) therapy based on reported left ventricular function. Results: One hundred and ninety patients were admitted to the CCU with a diagnosis of MI. Of these, 100 patients (51.5%) had an echocardiogram. Requirement for ICD therapy was unlikely in 87 (87%), probable in 6 (6%) and necessary in 7 (7%). Since a significant number of patients in the probable category were also likely to meet MADIT II criteria, we concluded that the proportion of patients requiring primary-prevention ICD therapy would be no less than 7% and more likely to be 13%. Conclusion: In the context of a busy teaching hospital, a figure of 13% for the requirement of ICD therapy in MI patients represents annual implantation activity of at least 100 per million. This is likely to have very significant resource implications.

References

  1. Myerburg RJ, Interian A, Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997;80: 10F-19F
  2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Structure, function, and time-dependence of risk. Circulation 1992; 85(suppl I): I2 - I10
  3. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Eng J Med 2001; 345: 1473 –82.
  4. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left- ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74.
  5. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82.
  6. Echt DS, Liebson PR, Mitchell LB, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Eng J Med 1991; 324: 781-8.
  7. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality and morbidity in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
  8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction: Multicenter Automatic Defibrillator Implantation Trial II. N Eng J Med 2002; 346: 877-883.
  9. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia : Multicenter Automatic Defibrillator Implantation Trial. N Eng J Med 1996; 335: 1933- 40.
  10. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley GA. A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unsustained Tachycardia Trial. N Eng J Med 1999; 341:1882- 90.
  11. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of anti-arrhythmic therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Eng J Med 1997; 337:1576 - 83.
  12. Cuser JP, Connelly DT. Implantable defibrillators for life threatening ventricular arrhythmias are more effective than antiarrhythmic drugs in selected high risk patients. Br Med J 1998; 317:762-3.
  13. Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302.
  14. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569-75.
  15. Gregoratos G, Abrams J, Epstein A, et al. ACC/AHA/NASPE 2002 Guideline update for implantation of ca for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/American Heart Assoication Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to update the 1998 Pacemaker Guidelines). Circulation 2002; 106: 2145 - 61.
  16. British Pacing and Electrophysiology Group. Guidelines for pacemaker follow up. Heart 1996; 76: 458-60.
  17. O’Donnell D, Bourke J, AnilKumar R, Simoneoidou E, Furniss S. Radiofrequency ablation for post-infarction ventricular tachycardia. Report of a single centre experience of 112 cases. Eur Heart J 2002; 23: 1699- 705.amison D, Creese A and Prentice T. The world health report 1999: making a difference. France: World Health Organization, 1999.

Downloads

Download data is not yet available.